Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsIVBIY 83 Market Cap is $23,669 Mil as of Sep. 05, 2026. GuruFocus rates IVBIY with a GF Score™ of 83/100 and a GF Value™ of $56.85 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,421 Biotechnology companies, Innovent Biologics ranks better than 98.73% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Innovent Biologics's share price for the quarter that ended in Dec. 2025 was $41.75. Innovent Biologics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 434 Mil. Therefore, Innovent Biologics's market cap for the quarter that ended in Dec. 2025 was $18,105 Mil.
Innovent Biologics's quarterly market cap
increased
from Dec. 2024 ($7,843 Mil) to Jun. 2025 ($11,988 Mil) and
increased
from Jun. 2025 ($11,988 Mil) to Dec. 2025 ($18,105 Mil).
Innovent Biologics's annual market cap
declined
from Dec. 2023 ($8,470 Mil) to Dec. 2024 ($7,843 Mil) but then
increased
from Dec. 2024 ($7,843 Mil) to Dec. 2025 ($18,105 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Innovent Biologics's Enterprise Value for Today is $21,497 Mil.
Innovent Biologics (OTCPK:IVBIY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Innovent Biologics Market Cap Related Terms
Innovent Biologics Market Cap Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Innovent Biologics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (IVBIY) has a Market Cap of $23,669 Mil as of Sep. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #18 out of 1421 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Innovent Biologics' Market Cap too high?
Innovent Biologics' current Market Cap is $23,669 Mil. The Biotechnology industry median Market Cap is 120.76. Innovent Biologics' value of $23,669 Mil is 19500.4% above this industry median. Based on the distribution chart, Innovent Biologics ranks #18 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innovent Biologics has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #18 out of 1421 companies for Market Cap. This places Innovent Biologics in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 120.76. Innovent Biologics' value of $23,669 Mil is 19500.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 120.76, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Market Cap of $23,669 Mil is 19500.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Market Cap is 120.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Market Cap is $23,669 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBIY) is currently considered Fairly Valued. The stock's GF Value™ is $56.85, compared to a current price of $54.29 — trading 4.5% below its estimated fair value. The current Market Cap is $23,669 Mil and 19500.4% above the Biotechnology industry median of 120.76. Innovent Biologics' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Innovent Biologics (IVBIY), the current Market Cap is $23,669 Mil as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (IVBIY) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of $54.29 is trading 4.5% below its estimated GF Value™ of $56.85.
GuruFocus considers Innovent Biologics to be Fairly Valued.
Key valuation signals for IVBIY:
Market Cap: $23,669 Mil
GF Value™: $56.85 vs. price of $54.29 (4.5% below fair value)
Industry Position: 19500.4% above the Biotechnology median (#18 of 1421)
No single metric tells the full story. See the IVBIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
83GF Score
Get the complete analysis for IVBIY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVBIY has been successfully added to your 
